                         SEQUENCE LISTING

<110>  Numab Innovation AG
 
<120>  NOVEL STABLE ANTIBODY VARIABLE DOMAIN FRAMEWORK COMBINATIONS

<130>  113879P877PC

<150>  EP17192206.5
<151>  2017-09-20

<160>  84    

<170>  PatentIn version 3.5

<210>  1
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp 
        35                  40                  45              


Met Gly Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr 
65                  70                  75                  80  


Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  2
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  2

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser 
            20                  25  


<210>  3
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  3

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly 
1               5                   10                  


<210>  4
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  4

Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  5
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  5

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  6
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  6

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp 
        35                  40                  45              


Met Gly Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr 
65                  70                  75                  80  


Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  7
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  7

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser 
            20                  25  


<210>  8
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  8

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly 
1               5                   10                  


<210>  9
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  9

Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu 
1               5                   10                  15      


Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  10
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  10

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  11
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  11

Gln Val Gln Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp 
        35                  40                  45              


Leu Ala Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln 
65                  70                  75                  80  


Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  12
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  12

Gln Val Gln Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser 
            20                  25  


<210>  13
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  13

Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala 
1               5                   10                  


<210>  14
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  14

Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr 
1               5                   10                  15      


Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  15
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  15

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  16
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  16

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Val Ser Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  17
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  17

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser 
            20                  25  


<210>  18
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  18

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 
1               5                   10                  


<210>  19
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  19

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln 
1               5                   10                  15      


Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  20
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  20

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  21
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  21

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln 
65                  70                  75                  80  


Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  22
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  22

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser 
            20                  25  


<210>  23
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  23

Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly 
1               5                   10                  


<210>  24
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  24

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys 
1               5                   10                  15      


Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  25
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  25

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  26
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  26

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Lys Val Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Val Thr Ile Ser Val Asp Ser Ser Lys Asn Gln 
65                  70                  75                  80  


Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  27
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  27

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Lys Val Ser 
            20                  25  


<210>  28
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  28

Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly 
1               5                   10                  


<210>  29
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  29

Arg Val Thr Ile Ser Val Asp Ser Ser Lys Asn Gln Phe Ser Leu Lys 
1               5                   10                  15      


Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  30
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  30

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  31
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  31

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Met Gly Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr 
65                  70                  75                  80  


Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  32
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  32

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser 
            20                  25  


<210>  33
<211>  18
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  33

Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn Trp Ala 
1               5                   10                  15      


Lys Gly 
        


<210>  34
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  34

Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln 
1               5                   10                  15      


Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  35
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  35

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  36
<211>  121
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  36

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Ile Asp Phe Asn Ser Asn 
            20                  25                  30          


Tyr Tyr Met Cys Trp Ile Arg Gln Ser Pro Gly Arg Gly Leu Glu Trp 
        35                  40                  45              


Leu Gly Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn 
    50                  55                  60                  


Trp Ala Lys Gly Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln 
65                  70                  75                  80  


Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr 
                85                  90                  95      


Tyr Cys Ala Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  37
<211>  25
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  37

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser 
            20                  25  


<210>  38
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  38

Trp Ile Arg Gln Ser Pro Gly Arg Gly Leu Glu Trp Leu Gly 
1               5                   10                  


<210>  39
<211>  31
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  39

Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn Gln Phe Ser Leu Gln 
1               5                   10                  15      


Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
            20                  25                  30      


<210>  40
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  40

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
1               5                   10      


<210>  41
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  41

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  42
<211>  23
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  42

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys 
            20              


<210>  43
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  43

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  44
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  44

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 
            20                  25                  30          


<210>  45
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  45

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
1               5                   10      


<210>  46
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  46

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  47
<211>  23
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  47

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys 
            20              


<210>  48
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  48

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  49
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  49

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys 
            20                  25                  30          


<210>  50
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  50

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
1               5                   10      


<210>  51
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  51

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  52
<211>  23
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  52

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys 
            20              


<210>  53
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  53

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
1               5                   10                  15  


<210>  54
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  54

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 
1               5                   10                  15      


Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys 
            20                  25                  30          


<210>  55
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  55

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
1               5                   10      


<210>  56
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  56

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110         


Gly 
    


<210>  57
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  57

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 
            100                 105                 110         


Gly 
    


<210>  58
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  58

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110         


Gly 
    


<210>  59
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  59

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 
65                  70                  75                  80  


Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 
            100                 105                 110         


Gly 
    


<210>  60
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  60

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110         


Gly 
    


<210>  61
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  61

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 
            100                 105                 110         


Gly 
    


<210>  62
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  62

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
1               5                   10      


<210>  63
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  63

Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 
1               5                   10      


<210>  64
<211>  20
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial linker sequence

<400>  64

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   10                  15      


Gly Gly Gly Ser 
            20  


<210>  65
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial linker sequence

<400>  65

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  66
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  66

Gln Ala Ser Glu Asn Ile Tyr Ser Phe Leu Ala 
1               5                   10      


<210>  67
<211>  7
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  67

Ser Ala Ser Lys Leu Ala Ala 
1               5           


<210>  68
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  68

Gln Gln Thr Asn Arg Tyr Ser Asn Pro Asp Ile Tyr Asn Val 
1               5                   10                  


<210>  69
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  69

Gly Ile Asp Phe Asn Ser Asn Tyr Tyr Met Cys 
1               5                   10      


<210>  70
<211>  18
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  70

Cys Ile Tyr Val Gly Ser His Val Asn Thr Tyr Tyr Ala Asn Trp Ala 
1               5                   10                  15      


Lys Gly 
        


<210>  71
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  71

Thr Ser Gly Ser Ser Val Leu Tyr Phe Lys Phe 
1               5                   10      


<210>  72
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  72

Gln Ala Ser Gln Ser Ile Ser Asp Trp Leu Ala 
1               5                   10      


<210>  73
<211>  7
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  73

Gly Ala Ser Arg Leu Ala Ser 
1               5           


<210>  74
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  74

Gln Gln Gly Trp Ser Asp Ser Tyr Val Asp Asn Leu 
1               5                   10          


<210>  75
<211>  10
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  75

Gly Phe Ser Leu Ser Ser Gly Ala Met Ser 
1               5                   10  


<210>  76
<211>  16
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  76

Val Ile Ile Ser Ser Gly Ala Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 
1               5                   10                  15      


<210>  77
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody CDR sequence

<400>  77

Arg Gly Gly Pro Asp Asp Ser Asn Ser Met Gly Thr Phe Asp Pro 
1               5                   10                  15  


<210>  78
<211>  122
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  78

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Lys Val Ser Gly Phe Ser Leu Ser Ser Gly 
            20                  25                  30          


Ala Met Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Val Ile Ile Ser Ser Gly Ala Thr Tyr Tyr Ala Ser Trp Ala Lys 
    50                  55                  60                  


Gly Arg Val Thr Ile Ser Val Asp Ser Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Pro Asp Asp Ser Asn Ser Met Gly Thr Phe Asp Pro Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  79
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  79

Phe Gly Cys Gly Thr Lys Leu Thr Val Leu Gly 
1               5                   10      


<210>  80
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody framework region

<400>  80

Phe Gly Cys Gly Thr Lys Val Thr Val Leu Gly 
1               5                   10      


<210>  81
<211>  113
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  81

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Gln Ala Ser Glu Asn Ile Tyr Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Lys Leu Ala Ala Gly Val Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 
65                  70                  75                  80  


Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Thr Asn Arg Tyr Ser Asn 
                85                  90                  95      


Pro Asp Ile Tyr Asn Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg 
    


<210>  82
<211>  111
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  82

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Asp Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Arg Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Trp Ser Asp Ser Tyr 
                85                  90                  95      


Val Asp Asn Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 
            100                 105                 110     


<210>  83
<211>  122
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  83

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Gly 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Val Ile Ile Ser Ser Gly Ala Thr Tyr Tyr Ala Ser Trp Ala Lys 
    50                  55                  60                  


Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Pro Asp Asp Ser Asn Ser Met Gly Thr Phe Asp Pro Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  84
<211>  122
<212>  PRT
<213>  artificial sequence

<220>
<223>  artificial antibody variable domain

<400>  84

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Gly 
            20                  25                  30          


Ala Met Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Val Ile Ile Ser Ser Gly Ala Thr Tyr Tyr Ala Ser Trp Ala Lys 
    50                  55                  60                  


Gly Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Pro Asp Asp Ser Asn Ser Met Gly Thr Phe Asp Pro Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


